Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · May 30, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with a specific type of blood cancer called Acute Promyelocytic Leukemia (APL) that has not responded to standard therapies, which include retinoic acid and arsenic. Researchers are testing a combination of two medications, Chidamide and Venetoclax, to see if they can help patients whose cancer is resistant to these usual treatments. The goal is to find out if this new therapy can be effective and safe for individuals facing this challenging situation.

To be eligible for the trial, patients must have a specific genetic marker (PML-RARα+) associated with APL and should not be in remission after receiving retinoic acid and arsenic treatment. Participants must have a life expectancy of at least three months and must be able to provide informed consent to join the study. Throughout the trial, patients will receive careful monitoring and support as they undergo this combination therapy. If you or someone you know has APL that hasn't responded to standard treatment, this trial could offer a potential new option to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with PML-RARα+ APL
• • Patients in non-remission status after treatment of RA combined with As
• • Patients with life expectance \>=3 months
• • Inform consent provided
• Exclusion Criteria:
• • Patients with incontrollable infection
• • Patients with life-expectancy less than 2 months
• • Patients with abnormal liver (\>3XN) and renal function (\>3XN）